1
|
Senhorães NR, Silva BF, Sousa R, Leite BP, Gonçalves JM, Almeida Paz FA, Pereira-Wilson C, Dias AM. Synthesis of 6,8-diaminopurines via acid-induced cascade cyclization of 5-aminoimidazole precursors and preliminary anticancer evaluation. Org Biomol Chem 2024; 22:1500-1513. [PMID: 38294067 DOI: 10.1039/d3ob01985c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
Inspired by the pharmacological interest generated by 6-substituted purine roscovitine for cancer treatment, 5-aminoimidazole-4-carboxamidine precursors containing a cyanamide unit were prepared by condensation of 5-amino-N-cyanoimidazole-4-carbimidoyl cyanides with a wide range of primary amines. When these amidine precursors were combined with acids, a fast cascade cyclization occurred at room temperature, affording new 6,8-diaminopurines with the N-3 and N-6 substituents changed relatively to the original positions they occupied in the amidine and imidazole moieties of precursors. The efficacy and wide scope of this method was well demonstrated by an easy and affordable synthesis of 22 6,8-diaminopurines decorated with a wide diversity of substituents at the N-3 and N-6 positions of the purine ring. Preliminary in silico and in vitro assessments of these 22 compounds were carried out and the results showed that 13 of these tested compounds not only exhibited IC50 values between 1.4 and 7.5 μM against the colorectal cancer cell line HCT116 but also showed better binding energies than known inhibitors in docking studies with different cancer-related target proteins. In addition, good harmonization observed between in silico and in vitro results strengthens and validates this preliminary evaluation, suggesting that these novel entities are good candidates for further studies as new anticancer agents.
Collapse
Affiliation(s)
- Nádia R Senhorães
- CQUM - Chemistry Centre, Department of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
| | - Bruna F Silva
- CQUM - Chemistry Centre, Department of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
| | - Raquel Sousa
- CQUM - Chemistry Centre, Department of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
- CEB - Centre of Biological Engineering, Department of Biology, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
| | - Bruna P Leite
- CQUM - Chemistry Centre, Department of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
| | - Jorge M Gonçalves
- CQUM - Chemistry Centre, Department of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
| | - Filipe A Almeida Paz
- CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
| | - Cristina Pereira-Wilson
- CEB - Centre of Biological Engineering, Department of Biology, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
- LABBELS - Associate Laboratory, 4710-057, Braga, Portugal
| | - Alice M Dias
- CQUM - Chemistry Centre, Department of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.
| |
Collapse
|
2
|
Barnadas-Carceller B, Martinez-Peinado N, Gómez LC, Ros-Lucas A, Gabaldón-Figueira JC, Diaz-Mochon JJ, Gascon J, Molina IJ, Pineda de las Infantas y Villatoro MJ, Alonso-Padilla J. Identification of compounds with activity against Trypanosoma cruzi within a collection of synthetic nucleoside analogs. Front Cell Infect Microbiol 2023; 12:1067461. [PMID: 36710960 PMCID: PMC9880260 DOI: 10.3389/fcimb.2022.1067461] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 11/11/2022] [Indexed: 01/14/2023] Open
Abstract
Introduction Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, and it is the most important neglected tropical disease in the Americas. Two drugs are available to treat the infection, but their efficacy in the chronic stage of the disease, when most cases are diagnosed, is reduced. Their tolerability is also hindered by common adverse effects, making the development of safer and efficacious alternatives a pressing need. T. cruzi is unable to synthesize purines de novo, relying on a purine salvage pathway to acquire these from its host, making it an attractive target for the development of new drugs. Methods We evaluated the anti-parasitic activity of 23 purine analogs with different substitutions in the complementary chains of their purine rings. We sequentially screened the compounds' capacity to inhibit parasite growth, their toxicity in Vero and HepG2 cells, and their specific capacity to inhibit the development of amastigotes. We then used in-silico docking to identify their likely targets. Results Eight compounds showed specific anti-parasitic activity, with IC50 values ranging from 2.42 to 8.16 μM. Adenine phosphoribosyl transferase, and hypoxanthine-guanine phosphoribosyl transferase, are their most likely targets. Discussion Our results illustrate the potential role of the purine salvage pathway as a target route for the development of alternative treatments against T. cruzi infection, highlithing the apparent importance of specific substitutions, like the presence of benzene groups in the C8 position of the purine ring, consistently associated with a high and specific anti-parasitic activity.
Collapse
Affiliation(s)
- Berta Barnadas-Carceller
- Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain
| | - Nieves Martinez-Peinado
- Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain,Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l’Alimentació, Universitat de Barcelona, Barcelona, Spain
| | - Laura Córdoba Gómez
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Granada, Spain
| | - Albert Ros-Lucas
- Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain,CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid, Spain
| | | | - Juan J. Diaz-Mochon
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Granada, Spain,GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain,Biosanitary Research Institute of Granada (ibs.GRANADA), University Hospitals of Granada-University of Granada, Granada, Spain
| | - Joaquim Gascon
- Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain,CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid, Spain
| | - Ignacio J. Molina
- Institute of Biopathology and Regenerative Medicine, Centre for Biomedical Research, University of Granada, Granada, Spain
| | - María José Pineda de las Infantas y Villatoro
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Granada, Spain,*Correspondence: Julio Alonso-Padilla, ; María José Pineda de las Infantas y Villatoro,
| | - Julio Alonso-Padilla
- Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain,CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III (CIBERINFEC, ISCIII), Madrid, Spain,*Correspondence: Julio Alonso-Padilla, ; María José Pineda de las Infantas y Villatoro,
| |
Collapse
|
3
|
Martinez-Peinado N, Lorente-Macías Á, García-Salguero A, Cortes-Serra N, Fenollar-Collado Á, Ros-Lucas A, Gascon J, Pinazo MJ, Molina IJ, Unciti-Broceta A, Díaz-Mochón JJ, Pineda de las Infantas y Villatoro MJ, Izquierdo L, Alonso-Padilla J. Novel Purine Chemotypes with Activity against Plasmodium falciparum and Trypanosoma cruzi. Pharmaceuticals (Basel) 2021; 14:ph14070638. [PMID: 34358064 PMCID: PMC8308784 DOI: 10.3390/ph14070638] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 06/24/2021] [Accepted: 06/26/2021] [Indexed: 11/16/2022] Open
Abstract
Malaria and Chagas disease, caused by Plasmodium spp. and Trypanosoma cruzi parasites, remain important global health problems. Available treatments for those diseases present several limitations, such as lack of efficacy, toxic side effects, and drug resistance. Thus, new drugs are urgently needed. The discovery of new drugs may be benefited by considering the significant biological differences between hosts and parasites. One of the most striking differences is found in the purine metabolism, because most of the parasites are incapable of de novo purine biosynthesis. Herein, we have analyzed the in vitro anti-P. falciparum and anti-T. cruzi activity of a collection of 81 purine derivatives and pyrimidine analogs. We firstly used a primary screening at three fixed concentrations (100, 10, and 1 µM) and progressed those compounds that kept the growth of the parasites < 30% at 100 µM to dose–response assays. Then, we performed two different cytotoxicity assays on Vero cells and human HepG2 cells. Finally, compounds specifically active against T. cruzi were tested against intracellular amastigote forms. Purines 33 (IC50 = 19.19 µM) and 76 (IC50 = 18.27 µM) were the most potent against P. falciparum. On the other hand, 6D (IC50 = 3.78 µM) and 34 (IC50 = 4.24 µM) were identified as hit purines against T. cruzi amastigotes. Moreover, an in silico docking study revealed that P. falciparum and T. cruzi hypoxanthine guanine phosphoribosyltransferase enzymes could be the potential targets of those compounds. Our study identified two novel, purine-based chemotypes that could be further optimized to generate potent and diversified anti-parasitic drugs against both parasites.
Collapse
Affiliation(s)
- Nieves Martinez-Peinado
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Álvaro Lorente-Macías
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain; (Á.L.-M.); (J.J.D.-M.)
- Institute of Biopathology and Regenerative Medicine, Centre for Biomedical Research, University of Granada, Avda. del Conocimiento s/n, 18100 Granada, Spain;
- Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK;
| | - Alejandro García-Salguero
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Nuria Cortes-Serra
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Ángel Fenollar-Collado
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Albert Ros-Lucas
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Joaquim Gascon
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Maria-Jesus Pinazo
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
| | - Ignacio J. Molina
- Institute of Biopathology and Regenerative Medicine, Centre for Biomedical Research, University of Granada, Avda. del Conocimiento s/n, 18100 Granada, Spain;
| | - Asier Unciti-Broceta
- Cancer Research UK Edinburgh Centre, Institute of Genetics & Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK;
| | - Juan J. Díaz-Mochón
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain; (Á.L.-M.); (J.J.D.-M.)
| | - María J. Pineda de las Infantas y Villatoro
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071 Granada, Spain; (Á.L.-M.); (J.J.D.-M.)
- Correspondence: (M.J.P.d.l.I.y.V.); (L.I.); (J.A.-P.); Tel.: +34-958249360 (M.J.P.d.l.I.y.V.); +34-932275400 (ext. 4569) (L.I.); +34-932275400 (ext. 4569) (J.A.-P.)
| | - Luis Izquierdo
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
- Correspondence: (M.J.P.d.l.I.y.V.); (L.I.); (J.A.-P.); Tel.: +34-958249360 (M.J.P.d.l.I.y.V.); +34-932275400 (ext. 4569) (L.I.); +34-932275400 (ext. 4569) (J.A.-P.)
| | - Julio Alonso-Padilla
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic—University of Barcelona, 08036 Barcelona, Spain; (N.M.-P.); (A.G.-S.); (N.C.-S.); (Á.F.-C.); (A.R.-L.); (J.G.); (M.-J.P.)
- Correspondence: (M.J.P.d.l.I.y.V.); (L.I.); (J.A.-P.); Tel.: +34-958249360 (M.J.P.d.l.I.y.V.); +34-932275400 (ext. 4569) (L.I.); +34-932275400 (ext. 4569) (J.A.-P.)
| |
Collapse
|
4
|
Lorente-Macías Á, Iañez I, Jiménez-López MC, Benítez-Quesada M, Torres-Rusillo S, Díaz-Mochón JJ, Molina IJ, Pineda de Las Infantas MJ. Synthesis and screening of 6-alkoxy purine analogs as cell type-selective apoptotic inducers in Jurkat cells. Arch Pharm (Weinheim) 2021; 354:e2100095. [PMID: 34128249 DOI: 10.1002/ardp.202100095] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 04/23/2021] [Accepted: 05/22/2021] [Indexed: 01/01/2023]
Abstract
Purines are ubiquitous structures in cell biology involved in a multitude of cellular processes, because of which substituted purines and analogs are considered excellent scaffolds in drug design. In this study, we explored the key structural features of a purine-based proapoptotic hit, 8-tert-butyl-9-phenyl-6-benzyloxy-9H-purine (1), by setting up a library of 6-alkoxy purines with the aim of elucidating the structural requirements that govern its biological activity and to study the cell selectivity of this chemotype. This was done by a phenotypic screening approach based on cell cycle analysis of a panel of six human cancer cell lines, including T cell leukemia Jurkat cells. From this study, two derivatives (12 and 13) were identified as Jurkat-selective proapoptotic compounds, displaying superior potency and cell selectivity than hit 1.
Collapse
Affiliation(s)
- Álvaro Lorente-Macías
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of "Chemistry Applied to Biomedicine and the Environment", Faculty of Pharmacy, University of Granada, Granada, Spain.,Institute of Biopathology and Regenerative Medicine, University of Granada, Granada, Spain
| | - Inmaculada Iañez
- Institute of Biopathology and Regenerative Medicine, University of Granada, Granada, Spain
| | - M Carmen Jiménez-López
- Institute of Biopathology and Regenerative Medicine, University of Granada, Granada, Spain
| | - Manuel Benítez-Quesada
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of "Chemistry Applied to Biomedicine and the Environment", Faculty of Pharmacy, University of Granada, Granada, Spain
| | - Sara Torres-Rusillo
- Institute of Biopathology and Regenerative Medicine, University of Granada, Granada, Spain
| | - Juan J Díaz-Mochón
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of "Chemistry Applied to Biomedicine and the Environment", Faculty of Pharmacy, University of Granada, Granada, Spain
| | - Ignacio J Molina
- Institute of Biopathology and Regenerative Medicine, University of Granada, Granada, Spain
| | - María J Pineda de Las Infantas
- Department of Medicinal & Organic Chemistry and Excellence Research Unit of "Chemistry Applied to Biomedicine and the Environment", Faculty of Pharmacy, University of Granada, Granada, Spain
| |
Collapse
|
5
|
The discovery of purine-based agents targeting triple-negative breast cancer and the αB-crystallin/VEGF protein–protein interaction. Med Chem Res 2018. [DOI: 10.1007/s00044-018-2275-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
6
|
Lorente-Macías Á, Benítez-Quesada M, Molina IJ, Unciti-Broceta A, Díaz-Mochón JJ, Pineda de Las Infantas Villatoro MJ. 1 H and 13 C assignments of 6-, 8-, 9- substituted purines. MAGNETIC RESONANCE IN CHEMISTRY : MRC 2018; 56:852-859. [PMID: 29677390 DOI: 10.1002/mrc.4743] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 01/25/2018] [Accepted: 03/19/2018] [Indexed: 06/08/2023]
Affiliation(s)
- Álvaro Lorente-Macías
- Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja, Universidad de Granada, Granada, Spain
- Instituto de Biopatología y Medicina Regenerativa, Centro de Investigación Biomedica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, 18016, Granada, Spain
| | - Manuel Benítez-Quesada
- Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja, Universidad de Granada, Granada, Spain
| | - Ignacio J Molina
- Instituto de Biopatología y Medicina Regenerativa, Centro de Investigación Biomedica, Parque Tecnológico de Ciencias de la Salud, Universidad de Granada, 18016, Granada, Spain
- Instituto de Investigación Biosanitaria ibs.GRANADA, Granada University Hospitals and University of Granada, Spain
| | - Asier Unciti-Broceta
- Ediburgh Cancer Research UK Centre MBC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4, 2XR, UK
| | - Juan José Díaz-Mochón
- Departamento de Química Farmacéutica y Orgánica, Facultad de Farmacia, Campus de Cartuja, Universidad de Granada, Granada, Spain
- Avenida de la Ilustración 114, Parque Tecnológico de Ciencias de la Salud, Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), 18016, Granada, Spain
| | | |
Collapse
|
7
|
Brahmayya M, Dai SA, Suen SY. Sulfonated reduced graphene oxide catalyzed cyclization of hydrazides and carbon dioxide to 1,3,4-oxadiazoles under sonication. Sci Rep 2017; 7:4675. [PMID: 28680037 PMCID: PMC5498654 DOI: 10.1038/s41598-017-04143-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 05/09/2017] [Indexed: 11/09/2022] Open
Abstract
Acid catalysts facilitate many chemical reactions. Sulfonated reduced grapheneoxide (rGOPhSO3H) has shown to be an encouraging solid acid catalyst because of its efficiency, cost-effectiveness and safety of use. In this study, we prepared the rGOPhSO3H nano acid catalyst, with the introduction of aromatic sulfonic acid radicals onto GO by fractional removal of oxygenated functions. It was thoroughly characterized by FT-IR, X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), Raman spectroscopy, energy dispersive spectroscopy (EDS) and solid state 13C MAS NMR (SSNMR). Here we report the conversion of CO2 (1.0 atm pressure, at = 50 °C, the source of C1 carbon feed stock) with hydrazides and a catalytic amount rGOPhSO3H, which through a cyclization reaction results in a new strategy for the synthesis of 5-substituted-3H-[1,3,4]-oxadiazol-2-ones (SOxdOs) under ultrasonic irradiation. Hence this concept of cyclization opens up for new insights
Collapse
Affiliation(s)
- Manuri Brahmayya
- Department of Chemical Engineering, National Chung Hsing University, 250 KuoKuang Raod, Taichung, Taiwan, R.O.C
| | - Shenghong A Dai
- Department of Chemical Engineering, National Chung Hsing University, 250 KuoKuang Raod, Taichung, Taiwan, R.O.C
| | - Shing-Yi Suen
- Department of Chemical Engineering, National Chung Hsing University, 250 KuoKuang Raod, Taichung, Taiwan, R.O.C..
| |
Collapse
|